Novartis Partners with Generate:Biomedicines for AI-Powered Protein Therapeutics
Disclosure: We might receive commission on purchases made through links on this page. Learn more.
Context and Background
Novartis is collaborating with Generate:Biomedicines to leverage its generative artificial intelligence (AI) platform for developing protein therapeutics across various disease areas. This partnership could potentially generate over $1 billion for Generate:Biomedicines, a pioneer in de novo protein generation.
The aim is to expedite protein-based drug development while reducing costs through a blend of machine learning (ML), experimental validation, and Novartis’ capabilities in target biology and clinical development.
Key Developments and Insights
Generate:Biomedicines’ CEO, Michael Nally, highlighted the shared commitment to overcoming challenges in protein therapeutics. The Generate Platform uses machine learning to analyze vast datasets of known proteins and peptides, identifying patterns to inform the design of new protein therapeutics.
This “generative biology” approach can reduce drug discovery timelines by about two years while enhancing success rates.
Novartis is making an upfront payment of $65 million, with more than $1 billion in milestone-based payments, emphasizing the strategic importance of this partnership. This collaboration is part of Novartis’s broader commitment to integrating AI into drug discovery, exemplified by its AI innovation lab established with Microsoft in 2019.
The platform’s modality and disease agnosticism allow application across various disease areas, including neuroscience and cardiovascular diseases. Generate’s technology has shown promise in creating functional antibodies and tackling traditionally difficult targets.
Impact and Significance
The partnership between Novartis and Generate:Biomedicines aims to revolutionize the development of protein therapeutics. By combining AI with extensive biological expertise, the companies intend to accelerate the discovery of first- and best-in-class therapeutic molecules.
This initiative underscores the importance of AI in modern drug development and highlights a trend towards more agile and innovative pharmaceutical R&D practices. The collaboration addresses key challenges in drug development, such as optimizing molecular design for manufacturability and scalability.
This effort is expected to benefit patients by providing faster access to groundbreaking treatments for diseases including cancer, immunology, and infectious diseases.
Generate:Biomedicines, backed by significant investment and partnerships, is well-positioned to leverage its cutting-edge technology for broader applications. This partnership with Novartis solidifies its role as a key player in the biotech industry and enhances Novartis’ capabilities in AI-driven drug discovery.
For more information, you can read the full article on Genetic Engineering & Biotechnology News.
I’m founder of BizStack at Cagri Sarigoz LLC and a passionate advocate for entrepreneurs.
With over 14 years in tech, marketing, and AI, including my role as Head of SEO at CitizenShipper and co-founder of TaleBot at Intale AI, I’m dedicated to sharing genuine, useful product insights and tips.
At BizStack, I aim to cut through the digital noise to provide clear, actionable advice.
And more than all else, I’m a father to a (always) little girl and a husband.
Contact me at [email protected] for assistance.
